303 related articles for article (PubMed ID: 30091530)
21. Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells.
Li JY; Tian T; Han B; Yang T; Guo YX; Wu JY; Chen YS; Yang Q; Xie RJ
World J Gastroenterol; 2023 Sep; 29(34):5038-5053. PubMed ID: 37753370
[TBL] [Abstract][Full Text] [Related]
22. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R
Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
25. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
27. A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers.
Zhu S; Chen Z; Wang L; Peng D; Belkhiri A; Lockhart AC; El-Rifai W
Clin Cancer Res; 2018 Apr; 24(8):1905-1916. PubMed ID: 29386219
[No Abstract] [Full Text] [Related]
28. SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma.
Xu G; Wang J; Wu Z; Qian L; Dai L; Wan X; Tan M; Zhao Y; Wu Y
J Proteome Res; 2014 Oct; 13(10):4211-9. PubMed ID: 25160476
[TBL] [Abstract][Full Text] [Related]
29. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
[TBL] [Abstract][Full Text] [Related]
31. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
33. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
34. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract][Full Text] [Related]
35. ING5 suppresses breast cancer progression and is regulated by miR-24.
Cui S; Liao X; Ye C; Yin X; Liu M; Hong Y; Yu M; Liu Y; Liang H; Zhang CY; Chen X
Mol Cancer; 2017 May; 16(1):89. PubMed ID: 28490335
[TBL] [Abstract][Full Text] [Related]
36. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
37. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
39. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Fandy TE; Shankar S; Ross DD; Sausville E; Srivastava RK
Neoplasia; 2005 Jul; 7(7):646-57. PubMed ID: 16026644
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
